Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis

Drug Name

CIMZIA® (certolizumab pegol)

Developed by

UCB

Therapy Class

Human monoclonal antibody

Current Indication

Plaque psoriasis

Market Sector

Dermatology

Development Status

Approved in the US and Europe
Expand

Go Top